Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Jorge Secada-Lovio

Cardiovascular Disease Towson, MD Medical Doctor

NPI 1316910011 CMS profile 105132

1122 Kenilworth Dr Ste 214, Towson, MD 21204

Open in the dashboard

General payments

$2,944

152 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Jorge Secada-Lovio of Towson, MD is reported in the CMS Open Payments database as having received $2,944 across 152 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 58th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $313 16
2023 General $551 30
2022 General $611 31
2021 General $898 46
2020 General $304 15
2019 General $268 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jorge Secada-Lovio
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Jorge Secada-Lovio were reported at $0. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Jorge Secada-Lovio Cardiovascular Disease median Middle half National median
2019 $268 $450 $127–$1,392 $163
2020 $304 $242 $77–$751 $114
2021 $898 $335 $101–$1,037 $132
2022 $611 $395 $121–$1,211 $149
2023 $551 $443 $136–$1,283 $160
2024 $313 $450 $136–$1,323 $164
2025 $0 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Novartis Pharmaceuticals Corporation $619 38 payments
  2. Amgen Inc. $594 29 payments
  3. Amarin Pharma Inc. $449 21 payments
  4. Esperion Therapeutics, Inc. $295 18 payments
  5. Sanofi-Aventis U.S. LLC $294 11 payments
  6. Janssen Pharmaceuticals, Inc $188 12 payments
  7. Abbott Laboratories $151 3 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $122 8 payments
  9. E.R. Squibb & Sons, L.L.C. $80 3 payments
  10. AstraZeneca Pharmaceuticals LP $74 5 payments
  11. Other $77 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $2,944 152 payments
Products named General payments · program years 2019–2024
  1. Repatha $594 29 payments
  2. Vascepa $406 19 payments
  3. ENTRESTO $314 22 payments
  4. NEXLETOL $295 18 payments
  5. LEQVIO $206 11 payments
  6. MULTAQ Cardiology/Vascular Diseases $199 5 payments
  7. XARELTO $188 12 payments
  8. Corlanor $113 5 payments
  9. ASSURITY $112 1 payment
  10. MULTAQ Cardiology/Vascular Diseases $83 5 payments
  11. Other $500 27 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

2,335

Median for Cardiology: 2,533

Drug cost

$359,192

Median for Cardiology: $485,213

Branded share of claims

20.9%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Repatha Sureclick Evolocumab Brand 165 $119,686
Eliquis Apixaban Brand 77 $86,979
Entresto Sacubitril/Valsartan Brand 45 $50,119
Jardiance Empagliflozin Brand 23 $27,408
Xarelto Rivaroxaban Brand 13 $19,782
Vascepa Icosapent Ethyl Brand 13 $13,288
Ezetimibe Generic 339 $12,537
Rosuvastatin Calcium Generic 250 $7,757
Atorvastatin Calcium Generic 364 $5,648
Metoprolol Succinate Generic 172 $3,458

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$148,932

Of which drugs: $1,393

Medicare patients

256

Average age 80

Services billed

2,393

123 women, 133 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 65%
Arthritis 47%
Atrial fibrillation 34%
Diabetes 28%
Chronic kidney disease 24%
Cancer 24%
Heart failure 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 46 184 $1,295

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $87
$87 165 —
NEXLETOL
  • Esperion Therapeutics, Inc. $74
$74 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $47
$47 — —
Ozempic
  • Novo Nordisk Inc $25
$25 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $22
$22 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

152 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record